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Abstract: Autism is a severe childhood disorder already presenting in the first 3 years of life and, therefore, strongly cor-
related with neurodevelopmental alterations in prenatal, as well as postnatal period. Neurotransmitters hold a pivotal role 
in development by providing the stimulation needed for synapses and neuronal networks to be formed during the critical 
period of neuroplasticity. Aberrations of the serotonergic system modify key processes in the developing brain and are 
strongly implicated in the pathophysiology of developmental disorders. Evidence for the role of serotonin in autism 
emerges from neuropathological, imaging and genetic studies. Due to its developmental arrest, autism requires early inter-
vention that would, among others, target the disrupted serotonergic system and utilize brain plasticity to elicit clinically 
important brain changes in children.  
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INTRODUCTION 
  Autism is a severe childhood disorder presenting in the 
first 3 years of life and affecting 1.3/1000 individuals [41]. It 
is the most common of pervasive developmental disorders 
(PDDs), which also include Rett disorder, Asperger’s   
syndrome, childhood disintegrative disorder and pervasive 
developmental disorder not otherwise specified [1,106]. 
Autism shows a high gender repartition with a male/female 
ratio varying from 1.33 to 16.0 in different studies and a 
mean male/female ratio of 4.3:1 [42], whereas it is character-
ized by deficit in three main areas: social interaction, verbal 
and non-verbal communication and restriction of activities 
and interests repertoire [105]. The symptoms spectrum is 
rather wide, including unusual sensory responses and motor 
patterns, pain insensitivity, gastrointestinal dysfunction, 
anxiety, depression, sleeping disturbances, attention issues 
and aggression or self-injury [69,106].  
  A variety of causal factors have been related to autism, 
including heredity, perinatal and environmental incidences, 
neuroanatomical changes, neurotransmitter aberrations etc. 
According to growing evidence, autism is a disorder of   
developmental arrest, rather than a progressive process and 
requires, therefore, the earliest possible intervention.  
  Neurotransmitter function in autism has long been under 
intense research, given the pivotal role of neurotransmitters 
in brain maturation and cortical organization [77]. The   
disruption of the serotonergic system is one of the most 
consistent and well-replicated findings in autism.   
  Serotonin is synthesized from the essential aminoacid 
tryptophan.L-tryptophanis hydroxylated to 5-hydroxytrypto-
phan (5-HTP) (by the rate-limiting enzyme tryptophan   
hydroxylase), which is subsequently decarboxylated by   
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aromatic-L-amino acid decarboxylase to be, eventually,   
converted to serotonin. Serotonin is cleared by the lung and 
the liver, except for a small amount that remains circulating 
and is stored in platelets. Serotonin does not cross the blood-
brain barrier and, therefore, the brain serotonin is exclusively  
synthesized in the central nervous system (CNS). It is 
catabolized there by monoamine oxidase A and the product 
is secreted into blood [70]. 
  The serotonergic system is one of the most widely   
distributed, as well as one of the earliest to develop in the 
mammalian embryo. The majority of neurons are located in 
the median and dorsal raphe nuclei. The first mainly pro-
vides fibres to the cortex and the latter to the hippocampus. 
The serotonergic system innervates almost all areas of the 
brain, whereas serotonin presents in non-serotonergic cells, 
as well, where it acts as a developmental signal [89]. Sero-
tonergic neurons can be detected in the human brain since 
the 5
th gestational week [92] and during the following 
months they grow and multiply rapidly. 
  The early appearance of the serotonergic system, as well 
as its intense activity during the first stages of development, 
indicate its role in the developmental process. Serotonin is 
reported to influence neurogenesis and/or neuronal removal, 
neuronal differentiation, synaptogenesis etc [103]. Among 
others, the serotonergic system modulates the activity of 
GABAergic interneurons, particularly the Cajal-Retzius 
cells, whereas it is released by axons projecting from the 
thalamus, thus playing a critical role in the establishment of 
thalamocortical afferents [10]. In addition, serotonin holds an 
important role in dendritic development, including overall 
dendritic length, spine formation and branching in both hip-
pocampus and cortex [103]. As far as it concerns the cortex, 
the serotonergic system also regulates the development of 
the barrel fields, which constitute an area of the primary   
somatosensory cortex and demonstrate a transient expression 
of serotonin terminals [103]. The early disturbance of the 
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contributes to several of the neuropathological changes in 
autism, as discussed below.  
  Serotonin has at least 14 different receptors, almost all of 
which are also involved in development. Activation of 
5HT1A receptors influences the length of dendrites and the 
number of dendritic spines in hippocampus [87], whereas the 
5HT2C receptors are involved in long-term potentiation in the 
hippocampus [94] and the 5HT2A in neuronal differentiation, 
dendritic maturation and modulation of brain-derived neu-
rotrophic factor levels [39,96]. 
  Apart from its role in development, serotonin is a signal-
ling molecule with a widespread distribution in the CNS, 
thus influencing almost every sphere of the mammalian 
physiology: cardiovascular regulation, respiration, gastroin-
testinal system, pain sensitivity, thermoregulation, circadian 
rhythm, appetite, aggression, sensorimotor activity, sexual 
behavior,mood,cognition, learning and memory [89]. There-
fore, several symptoms caused by a possible serotonergic 
disturbance would be common with the most usual charac-
teristics of autism.     
  Increase of platelet serotonin was the first finding to im-
ply the involvement of the serotonergic system in the patho-
genesis of autism. Literature suggests that hyperserotonemia 
is present in 25-50% of individuals with autism, as well as 
their first-degree relatives [2,27], whereas parents of children 
with autism are more likely to present serotonin-related psy-
chiatric disorders, such as depression or obsessive compul-
sive disorder [27,34].  
  Nevertheless the elevation in blood, there are indications 
that serotonin is actually decreased in the brain. Tryptophan 
depletion experiments have led to exacerbation of many re-
petitive behaviors (particularly whirling, flapping, pacing, 
banging and hitting themselves, rocking and anxiety) [64], 
whereas serotonergic agents, such as selective serotonin re-
uptake inhibitors (SSRIs), have proven beneficial for patients 
with autism [57]. The reported decrease in the ratio of serum 
tryptophan to large neutral amino-acids probably indicates a 
low availability of tryptophan in the autistic brain [33], 
whereas administration of 5-HTP has led to substantial in-
crease of serotonin concentration in blood of patients, con-
trary to controls, on whom it had no impact [31]. In addition, 
animal studies have identified a serotonin depletion model of 
neonatal mice that mimics neurochemical and structural 
changes in cortex and also displays a behavioral phenotype 
consistent with autism [14,47]. As far as it concerns humans, 
it has been reported that the severity of at least one specific 
behavioral dimension in autism (repetitive behaviors) paral-
lels the sensitivity of the 5HT1D receptor [48].  
  Neuroimaging, neuropathological and genetic studies 
have added to the evidence for the large-scale involvement 
of serotonin in pathogenesis and, therefore, also in treatment 
of autism. 
NEUROIMAGING STUDIES 
  Functional neuroimaging studies have proven the de-
crease of serotonin synthesis in children with autism aged 2-
5 years, as well as the focal aberrations of serotonin synthe-
sis and the low binding potentials of the serotonin trans-
porter and receptor in individuals with PDDs. 
  Functional neuroimaging studies have shed light into 
synthesis, as well as binding capacity, of serotonin in indi-
viduals with autism. According to positron emission tomo-
graphy (PET) studies, children aged 2 to 5 years normally 
undergo a period of increased serotonin synthesis capacity 
(200% of adult values), followed by a decline toward adult 
values between the ages of 5 and 14 years. In contrast,   
patients with autism demonstrate -until the age of 5- a re-
duced capacity for synthesis, which, however, increases to 
reach and overcome adults’ values by the age of 15 [23]. 
Therefore, the hyperserotonemia, which probably appears in 
older patients, does not actually develop before an age when 
most diagnoses of autism have been already made [45].  
  It has been indicated that the developmental pattern of 
serotonin synthesis in non-autistic children strongly resem-
bles the profile of synaptic density in their frontal cortex, as 
demonstrated in PET and post mortem studies respectively 
[10]. The normal process of high brain serotonin synthesis 
and synaptogenesis during preschool years is highly dis-
rupted in children with autism.  
  Apart from global abnormalities, PET studies have also 
revealed focal aberrations of serotonin synthesis with cortical 
asymmetry in serotonin uptake. Patients with reduced syn-
thesis on the left side demonstrate high frequency of severe 
language impairment, whereas the decrease on the right side 
represents higher frequency of left- or mixed-handedness. 
The asymmetries have been attributed, among others, to the 
general developmental misregulation of serotonin synthesis 
or to an early damage of the left dominant hemisphere, lead-
ing to compensatory changes on the right side [20]. 
  In addition, studies with single-photon emission com-
puted tomography (SPECT) have revealed the low binding 
capacity of the serotonin transporter in the medial frontal 
cortex, midbrain, and temporal lobe areas [63], whereas PET 
and SPECT investigations have determined the reduced 
binding capacity of the cortical serotonin type 2-receptor in 
individuals with PDDs, as well as parents of children with 
autism [43,71]. The low binding potentials have been attrib-
uted to the diminished serotonergic nerve terminals and 
sparse synapse density. 
NEUROPATHOLOGICAL STUDIES 
  The serotonergic disruption during development is in-
volved in some of the most consistent neuropathological 
findings in the autistic brain, such as the alteration of the 
minicolumns, the limbic system and the cerebellum.  
  One of the major neuropathological findings in the autis-
tic brain is the disruption of neocortical minicolumns, which 
are the primary anatomical units with the lowest level of 
neocortical modularity. The disruption of minicolumns leads 
to aberrant cortical organization, clinically correlated with 
altered information processing and perhaps with the “hyper-
specific” autistic brain. Minicolumns in autistic brains have 
been reported to be more numerous, but smaller and closely 
spaced, compared to controls.  Furthermore, their constituent 
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density, whereas the surrounding neuropil is significantly 
reduced [17,18]. The very detailed focusing, along with the 
failure to recognize broader contexts of information are 
probably some of the functional consequences of narrow 
minicolumns [10]. A tentative case for the explanation of 
this narrowing can be made for serotonergic disturbances 
[45].  
  Serotonin has been recently shown to hold a pivotal role 
in corticogenesis, mainly through the serotonergic innerva-
tion of Cajal Retzius cells in the cortex. Cajal Retzius are 
reelin-expressing neurons modulating the cortical laminar 
and columnar organization [74]. Reelin has been long shown 
to be reduced in autism [40]. Rodent studies with early ma-
nipulation of the serotonergic system, causing or mimicking 
a serotonin increase, have reported disruption of the seroton-
ergic input to Cajal Retzius cells, reduction of brain reelin 
levels [53] and perturbing of cortical organization [53,107]. 
Conversely, depletion of serotonin in neonatal rodents has 
caused delayed development [76] and aberrant appearance of 
the thalamocortical pattern [12], as well as decreased size of 
the barrel fields [73,79]. It is noteworthy that during the first 
postnatal days, rodents show a peak in serotonin levels, simi-
lar to the increased serotonin synthesis of humans at the age 
of 2 years [77].   
  Another well replicated finding in autism is the alteration 
of the amygdala, affecting its volume, cellpacking density 
and activation during processing [46,90]. The central nucleus 
of the amygdala receives intense innervation from serotoner-
gic dorsal raphe neurons. Rodent studies with prenatal and 
neonatal manipulation of serotonin (mimicking hypersero-
tonemia) have reported an increase in calcitonin-gene related 
peptide (CGRP) in the central nucleus of the amygdala 
[104]. CGRP is probably involved in conditioned responses 
to acoustic or somatosensory stimuli and may play a role in 
fear conditioning [56]. The amygdala is considered to hold a 
significant role in autism, mainly through its involvement in 
the developmental deficit in emotion processing and, gener-
ally, in social perception [85]. 
  Animal studies with neonatal serotonin depletion have 
shown a significant decrease of synaptic spine density in the 
hippocampus [108], as well as a reduction in serotonergic 
innervation to the hippocampus and the cortex [47]. The hip-
pocampus is critical, among others, for episodic memory, 
which has been repeatedly reported to be impaired in autism 
[59]. It has been, additionally, shown that the autistic hippo-
campus has reduced neuronal cell size and increased cell-
packing density [7]. 
  Rodent studies with prenatal and neonatal manipulation 
of serotonin (mimicking hyperserotonemia) have also proven 
a loss of oxytocin-containing cells in the hypothalamus 
[104]. Among other actions, oxytocin is involved in social 
recognition and affiliative (or prosocial) behaviors [22], 
which are severely disturbed in autism.    
   As far as it concerns the cerebellum, its transiently high 
expression of serotonin receptors in rodents during the first 2 
postnatal weeks suggests an association between the de-
crease in Purkinje cells and the altered serotonergic system 
[5,24,68]. In addition, it has been reported that mice lacking 
the gene for reelin and, consequently, the normal reelin   
levels, demonstrate a reduction in Purkinje cells [10]. Brain 
reelin levels are affected not only by the lack of the reelin 
gene, but also by the serotonergic disruption [53], which 
may, therefore, be involved in the  decrease of Purkinje   
neurons. The reduction of Purkinje cells is one of the most 
apparent and consistent neuropathologic findings in autism 
[7].   
GENETIC STUDIES 
  Molecular approaches with case-control and family-
based studies have revealed a number of serotonin-related 
candidate genes in autism.  Some of them are, additionally, 
involved in the appearance of gender differences in PDDs. 
  Tryptophan hydroxylase-2 (TPH2) is the rate limiting 
enzyme for CNS serotonin synthesis and is encoded by 
TPH2, whereas TPH1 encodes the peripheral isoform of the 
enzyme. Only one report has provided preliminary evidence 
for the involvement of TPH2 variants in autism [29], 
whereas following research has failed to confirm the associa-
tion for either TPH1 or TPH2  [81,83]. Nevertheless, both 
genes have been shown to hold critical roles in the homeo-
stasis of peripheral and brain serotonin respectively 
[8,32,51].  
 SLC6A4 is a second candidate gene with a repeatedly 
reported causal link to autism [21,28,38,80,93,98,101]. It is 
located on 17q.11 and encodes the serotonin transporter. It 
contains over 20 polymorphisms, of which two are the most 
interesting in neuropsychiatry: 5-HTTLPR and VNTR [72]. 
5-HTTLPR is a promoter region polymorphism reported to 
influence cerebral cortical grey matter volume [98], hippo-
campal volume and amygdala response [86]. In addition, it 
has been associated with the presence of conduct disorder, 
aggressivity and ADHD only in male individuals [15]. How-
ever, recent genetic studies, as well as a meta-analysis on 
polymorphisms’ relation to autism, have produced contro-
versial results, raising concerns regarding the involvement of 
SLC6A4 in autism [21,52,82]. The inconsistent findings 
could be associated with ethnic diversity, methods of genetic 
analysis and genetic heterogeneity of the disorder [21]. It is 
noteworthy that the serotonin transporter is expressed in the 
placenta [6] and, therefore, a maternal modifier effect could 
potentially pose risk for autism in the child [20]. 
  Evidence for an association with autism exists for several 
serotonin receptors genes: HTR1B [75], HTR2A [21], HTR3A 
[3], HTR5A [30] and HTR7 [32], whereas other studies have 
reported controversial findings [97]. Ongoing and future 
investigations will probably replicate or produce new results. 
 MAOA, the gene encoding monoamine oxidase, contains 
a promoter polymorphism (upstream variable number tan-
dem repeats, uVNTR) with a high and a low activity allele. 
The latter has been consistently associated with cortical en-
largement [36], as well as lower intelligence and more severe 
autistic behaviour [25] in children with autism, whereas, in 
healthy individuals, it has been related to increased activity 
in the amygdala and hippocampus and impaired cingulate 
activation during cognitive inhibition [66]. The MAOA poly-
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in the intelligence of children with autism through the intrau-
terine environment [54]. In addition, an association of autism 
with several MAOA haplotypes was recently identified, thus 
suggesting the presence of a causable polymorphism in the 
haplotype block [109]. 
  The b3-integrin gene ITGB3 is identified as a quantitative 
trait locus for blood serotonin levels, primarily in males.
ITGB3  has been reported to show genetic and expression 
interaction with SLC6A4, leading to increase of autism sus-
ceptibility [30,101]. Other interactions involving SLC6A4
with  TPH1 or HTR1D or HTR5A, as well as ITGB3 with 
HTR1A or HTR5A and TPH1 with MAOA, have been also 
identified [30, 51]. 
  It should be noted that genetic studies of the serotonergic 
system have revealed a number of gender-related differ-
ences. 5-HTTLRP is associated with the presence of aggres-
siveness and ADHD in males only [15] and MAOA is located 
on the X chromosome [99], whereas the Leu33 allele in 
ITGB3 has been suggested to have a dominant effect in 
males and a recessive effect in females, as far as it concerns 
association to autism [100]. In addition, human and animal 
studies have respectively shown that ITGB3 [55,84], as well 
as SLC6A4 [78], mRNA expressions are reduced by estro-
gens. Biochemical and neuroendocrine studies have also 
demonstrated sex related differences. For example, the mean 
whole blood serotonin level is higher in women [99], the 
female serotonergic system shows greater response to stimu-
lation with serotonergic agents [88] and SSRIs are more ef-
fective in treating women with depression [58]. As far as it 
concerns development, sex-differences of the serotonergic 
system have been reported to present rather early and to con-
tribute to dimorphic cortical development [26]. It is, there-
fore, possible that the serotonergic disturbances are involved 
in the appearance of the gender differences in autism.  
NEURODEVELOPMENTAL INTERVENTION 
  Early developmental intervention is of ultimate impor-
tance in order to utilize brain plasticity and provide perma-
nent and substantial benefit. However, the administration of 
any pharmacological treatment to children would first re-
quire a large number of animal studies, in order to assess 
the balance between possible gain and damage. 
   Another line of research on the serotonergic involvement 
in autism comes from pharmacological intervention with 
serotonergic agents.  
  A significant loss of serotonin terminals, along with de-
creased metabolic activity in cortex, seizures and “autistic-
like” behaviors have been noted in rats, which had been ad-
ministered with a serotonin agonist, 5-methoxytryptamine, 
during early development. The rat hyperserotonemia model 
is consistent with autistic humans during the very early 
stages of development, when the still incomplete blood-brain 
barrier allows high blood serotonin to enter the brain and 
cause the loss of serotonin terminals through a negative 
feedback effect [65]. 
  Regardless the underlying mechanisms of the serotonin 
disruption, it has been repeatedly reported that SSRIs dem-
onstrate therapeutic benefit in patients with PDDs. SSRIs 
influence both peripheral and central levels of serotonin [57] 
and have been utilized against various symptoms of the dis-
order [37,49,50]. Although they do not directly affect com-
munication and social deficits, they do improve repetitive 
behaviours [50] and behavioural control, thus resulting in 
“prosocial behaviour and subsequent progress in communi-
cation” [57]. A number of symptoms (aggression, self-injury, 
stereotypies, irritability, temper tantrums) are reported to 
improve, whereas adverse effects include aggressiveness, 
agitation, motor hyperactivity, sedation, insomnia, anxiety, 
headaches, appetite changes, behavioral activation etc [57].  
  Intense controversy exists regarding the use of SSRIs in 
children. Due to its neurodevelopmental arrest, autism re-
quires rather early intervention that would elicit clinically 
important brain changes in children. Reports on SSRIs ad-
verse effects, especially when the exposure occurs in utero or 
in early childhood are controversial [9,10], whereas rodent 
studies have reported potential late-emerging adverse effects 
after early administration of SSRIs [4]. Increased extracellu-
lar serotonin levels during the perinatal period of mice are 
associated with subtle changes in brain circuitry and mal-
adaptive behaviours, which are maintained into adulthood 
[13]. Up to now few data exist on SSRIs use in preschool age 
or even childhood [57]. In addition, the Food and Drug Ad-
ministration has issued a controversial public health warning 
about a causal link between the use of SSRIs and paediatric 
suicidality [44].  
  A number of clinical studies would be necessary before 
sufficient evidence mounts to include SSRIs as a standard in 
autism care [57], whereas SSRIs use in children, especially 
as early intervention, would certainly require a great amount 
of caution.  
  Ongoing investigations on SSRIs are nowadays focusing 
on issues of safety and efficacy in an attempt to assess the 
balance between possible gain and damage [49]. Pharmaco-
genomics research can tremendously contribute to this direc-
tion by identifying genetic predictors of individuals’ re-
sponse and tolerability. 
  It has already been reported that 5-HTTLPR polymor-
phism may influence the individual responses to fluvoxam-
ine administration in childhood autism [91]. In addition, 
animal studies have revealed that mice with functionally 
different allelic forms of TPH2 and consequent impairment 
of serotonin synthesis do not respond to SSRIs, whereas the 
SSRIs antidepressant-like effect is reinstated, when the sero-
tonin synthesis is enhanced by pre-treatment with trypto-
phan. It has been, conclusively, proven that administration of 
a serotonin precursor stimulates serotonin synthesis and, 
subsequently, improves SSRIs effect in mice carrying the 
mutated enzyme [16,19].   
  Therefore,inaddition to SSRIs, other serotonergic agents, 
such as 5-HTP, could be probably considered as alternative, 
developmental interventions. Tryptophan depletion has al-
ready been reported to cause deterioration in patients with 
autism [64], whereas an oral challenge with 5-HTP had no 
impact in controls, but led to increase in serotonin blood 
concentration in patients [31]. Surprisingly, the clinical ef-154    Current Neuropharmacology, 2009, Vol. 7, No. 2 Zafeiriou et al. 
fects of 5-HTP administration in individuals with autism 
have not yet been studied.     
  5-HTP is commercially produced by extraction from the 
plant Griffonia simplicifolia and is typically available as the 
L-enantiomer, where most of the biological activity resides 
[95]. Its half-life is relatively short (4.3 ± 2.8 hours) [102] 
and the time to maximal concentration is 1–2 hours [62]. It is 
well absorbed from an oral dose with approximately 70% 
ending up in the bloodstream [60,61] and its absorption is 
not affected by the presence of other amino acids [11].  
  Contrary to L-tryptophan, 5-HTP crosses the blood-brain 
barrier with no requirement for a transport molecule. Its pri-
mary function is the elevation of serotonin within the CNS. 
Unlike L-tryptophan, 5-HTP cannot be shunted into niacin or 
protein production and is exclusively used on the metabolic 
pathway of serotonin synthesis. A number of studies have 
investigated the effect of 5-HTP in depression, reporting 
similar efficacy and tolerability to SSRIs. 5-HTP has, addi-
tionally, been used in fibromylagia, insomnia, obesity etc 
[11].   
  One major concern regarding the use of 5-HTP would be 
the risk of eosinophilia-myalgia syndrome. The disease pre-
sented in the 1980s, due to contamination of commercial 
tryptophan supplements. It was associated with faulty pro-
duction methods using bacterial fermentation and, therefore, 
it would be rather unlikely to occur after use of the naturally 
produced 5-HTP [11,35,67]. Nevertheless, the administration 
of 5-HTP would require constant and close monitoring. A 
second concern is a potential serotonin syndrome, resulting 
from excess amounts of serotonin in the peripheral circula-
tion. This can be easily prevented with the co-administration 
of 5-HTP and carbidopa. Carbidopa is a peripheral decar-
boxylase inhibitor, diminishing 5-HTP peripheral conversion 
into serotonin and, consequently, improving its availability 
in the CNS [95].  
  Taken into account that a number of neuropathological 
changes in the autistic brain are highly associated with the 
reduced CNS serotonin levels and that 5-HTP has an obvious 
role in increasing serotonin synthesis in the brain, it would 
be reasonable to consider the use of 5-HTP as an alternative, 
developmental intervention for children with autism.  
  However, the potential administration of 5-HTP as early 
treatment would arise a multitude of limitations. 5-HTP has 
not yet been widely tried in populations of adult patients 
with depression and has certainly not been tried in autism. 
Prior to its administration to children, a lot of questions re-
garding efficacy and safety should be addressed. Secondly, 
the reduced CNS serotonin might only represent a small part 
of a more generalized disruption, which causes the autistic 
phenotype and can obviously not be treated merely by sero-
tonergic agents. Thirdly, any developmental serotonergic 
treatment would largely target the reduced serotonin levels in 
early life of patients. However, serotonin synthesis in autistic 
children is still being under investigation, whereas human 
studies only concern ages older than 2 years. Last but not 
least, it has not been examined whether early treatment with 
5-HTP would have side effects over both the short and the 
long term [10]. Therefore, a large number of experiments on 
animals, as well as animal models for autism, would be ut-
terly necessary before any early pharmacological interven-
tion, especially in the form of serotonergic agents, is initiated 
in a human study.  
CONCLUSION 
  According to accumulating evidence from imaging, neu-
ropathological and genetic studies, autism is a disorder of 
developmental arrest and, therefore, requires early treatment. 
Developmental intervention can utilize brain plasticity to 
provide permanent and substantial benefit. Up to now, early 
treatment consists solely of occupational or physical therapy, 
while no pharmacological intervention has been systemati-
cally used. Ongoing research aims to ascertain the safety and 
efficacy of various agents, including the ones targeting the 
disrupted serotonergic system. It has been speculated that 
part of the early damage could be prevented by providing the 
autistic brain with adequate serotonin levels. The use of 
SSRIs in autism is currently under intense research, whereas 
another alternative developmental intervention, the early 
administration of 5-HTP, is being suggested as a potentially 
promising option. However, any pharmacological early in-
tervention needs to be largely tried on animals, as well as 
animal models for autism, before any human studies are in-
stigated.
  The identification of safe and efficacious pharmacologi-
cal developmental intervention, along with related issues of 
pharmacogenomics, are essential parts of future research in 
autism. 
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